Inovio’s Future Hinges on Critical Regulatory Submission
Veröffentlicht: 05.09.2025 um 10:18 Uhr, Redaktion boerse-global.deInovio Pharmaceuticals shares edged higher in early trading, gaining 1.48% to reach $2.75. This modest uptick follows the company’s participation at the H.C. Wainwright Annual Global Investment Conference, where management is scheduled to deliver prepared presentations and conduct one-on-one meetings with potential investors.
Recent quarterly results released on August 12 reveal a strengthened financial position for the biotechnology firm. The company has demonstrated notable progress in several key areas:
- Net losses narrowed significantly to $23.5 million, compared to $32.2 million in the previous period
- Research and development expenditures were reduced by 30% to $14.5 million
- General and administrative costs decreased by 16% to $8.6 million
This improved financial discipline, combined with a July capital raise that generated approximately $22.5 million, Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
